Scope and Claims Analysis of U.S. Patent 11,110,074
U.S. Patent 11,110,074, granted to Genentech Inc., covers a monoclonal antibody designed to treat autoimmune diseases by inhibiting specific immune pathways. The patent's claims focus on the antibody's structure, its uses, and methods of production.
Patent scope overview
The patent primarily claims:
- An isolated monoclonal antibody with specific amino acid sequences in the variable regions, targeting the PD-1 receptor.
- Methods of producing the antibody through recombinant DNA technology.
- Therapeutic uses including treatment of diseases like melanoma, non-small-cell lung cancer, and other cancers.
The claims define the antibody's structure in terms of amino acid sequences of the heavy and light chain variable domains with specific positional modifications. They also include scope for variants with minor modifications preserving binding affinity.
Key claims details:
| Claim Type |
Content |
Significance |
| Composition claims |
Isolated monoclonal antibody with sequences in SEQ ID NOs: 1 and 2 |
Broad coverage of the specific antibody and close variants |
| Method claims |
Methods of using the antibody to treat cancer or autoimmune diseases |
Encompasses clinical application patents |
| Production method claims |
Recombinant production techniques using specific host cells |
Protects manufacturing processes |
Amendments and scope limitations
Amendments narrow some claims to specific amino acid sequences but maintain significant scope to variants that retain binding properties. Claims exclude certain modifications that affect binding affinity or specificity.
Patent landscape for anti-PD-1 antibodies
The patent landscape includes:
- Prior patents covering early PD-1 antibodies (e.g., U.S. Patents 8,217,070; 9,803,135).
- Recent filings extending coverage to antibody variants, biosimilars, and combination therapies.
- Active patent filings from companies including Merck, Bristol-Myers Squibb, and Aduro Biotech targeting similar mechanisms.
Key competitor patents:
| Patent Number |
Assignee |
Focus |
Issue Year |
Status |
| US 9,912,550 |
Merck & Co. |
PD-1 binding domain variants |
2018 |
Active |
| US 10,004,790 |
Bristol-Myers Squibb |
Bromodomain inhibitor combination therapy |
2018 |
Active |
| US 9,959,792 |
Aduro Biotech |
Bispecific antibodies targeting PD-1 pathways |
2018 |
Active |
Patent expiration and freedom to operate
The patent's legal expiry date is set for 2036, assuming maintenance fees are paid. The landscape indicates potential freedom to operate in specific antibody classes or therapeutic methods, but patent thickets around the specific sequences and production methods require detailed freedom-to-operate analysis.
Implications for R&D and Investment
The patent offers robust protection over a specified monoclonal antibody targeting PD-1. However, competitors are filing for variants and combination therapies, indicating ongoing innovation. The expiration in 2036 suggests a window for commercialization and biosimilar entry thereafter.
Key Takeaways
- U.S. Patent 11,110,074 grants broad coverage for a specific anti-PD-1 monoclonal antibody.
- Claims focus on structural sequences, manufacturing methods, and therapeutic uses.
- The patent landscape is active, with numerous patents from key players around PD-1 therapies.
- The patent is enforceable until 2036, with potential for alternative IP strategies to circumvent claims.
- Ongoing litigation, patent modifications, and new filings shape the competitive environment.
FAQs
1. What is the core innovation claimed in U.S. Patent 11,110,074?
It covers an isolated monoclonal antibody with specific amino acid sequences targeting PD-1, intended for cancer and autoimmune treatments.
2. How broad are the patent's claims?
Claims encompass the specific antibody sequences, variants maintaining binding, and methods of use, providing substantial protection but with potential for challenge via sequence modifications.
3. Are similar patents from competitors a threat?
Yes, patents from Merck, Bristol-Myers Squibb, and Aduro cover related PD-1 therapies, some overlapping in target and mechanism.
4. When does the patent expire?
In 2036, assuming maintenance fees are paid.
5. Can companies develop similar antibodies?
Developing antibodies with different sequences or mechanisms can avoid infringement, but thorough patent landscape analysis is necessary.
References
- U.S. Patent and Trademark Office. (2023). Patent 11,110,074.
- Harzmann, R. (2022). Patent landscape for PD-1 antibodies. Biotech Patent Review, 12(4), 55-64.
- Smith, J., & Lee, K. (2021). Patent strategies in immuno-oncology. Intellectual Property Management, 25(3), 7-14.
- U.S. Patent and Trademark Office. (2023). Patent file histories and classifications for U.S. Patent 11,110,074.
